-
More than $35 billion! 278 pharmaceutical companies invested in research and development exposure
Time of Update: 2021-03-07
Xiang Xue Pharmaceutical invested 193 million yuan in research and development, an increase of 294.06 percent over the same period last year, accounting for 10.65 percent of operating income.
-
Direct drop of 40,000 yuan 257 kinds of consumables the lowest price in the country announced
Time of Update: 2021-03-07
According to Cypress Blue equipment combing, this high-value supplies price adjustment involves electrophysiology, non-vascular implants, joints, oral, neurosurgery, in vitro circulation and blood purification, vascular intervention and other consumables, involving Belang Medical, Poco, Fesenjus, Shanghai minimally invasive, Xeronic and other well-known domestic and foreign equipment products.
-
Heavy Pharmaceuticals acquired a 51% stake in Chongqing Changsant Pharmaceutical Co., Ltd
Time of Update: 2021-03-07
Upon completion of this transaction, Changssheng Pharma will become a subsidiary within the scope of the consolidated statements of listed companies.
This transaction does not constitute an associated transaction, nor does it constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies.
-
Drugstores sell prescription drugs and another round of vexed inspections
Time of Update: 2021-03-07
During the business hours of a pharmaceutical retail enterprise, a practicing pharmacist or other pharmaceutical technician who has been qualified according to law is not on duty; Penalties: Order to make corrections within a time limit; if the time limit is not corrected or the circumstances are serious, the scope of operation of prescription drugs or Class A over-the-counter drugs shall be reduced, and a fine of 3,000 yuan to 10,000 yuan or less shall be imposed.
-
Hua-Li Pharmaceuticals Obtains Dozagliatin's License for Drug Production
Time of Update: 2021-03-07
Since this year, Hua-Yuan Pharmaceuticals has successfully completed two key milestones in the registration of clinical trials for the listing of two new phase III drugs, including the Phase III clinical trial SEED (HMM0301) for the single-drug treatment of Dozagliatin in patients with undigested type 2 diabetes, and the clinical trial OFN (HMM0302) for a combined drug trial of metformin in patients with type 2 diabetes who failed to complete the treatment of metformin.
-
Sapp Ace will list its subsidiary Strong Body Pharmaceuticals
Time of Update: 2021-03-07
the evening of November 23rd, Sappes announced that in order to optimize the allocation of resources, improve the profitability of assets and enhance the sustainable development capacity, the compan
-
Seven years after the U.S. stock market was de-listed, Synth Pharmaceuticals listed on the Hong Kong Stock Exchange
Time of Update: 2021-03-07
Although the core revenue of Synth Pharmaceuticals still relies on traditional products, nearly 50 new drugs in the future will inevitably bring new changes to China's pharmaceutical industry.
-
Jilin governance of high-value medical supplies to implement the national unified supplies coding
Time of Update: 2021-03-07
Carry out dynamic maintenance on the national platform, strengthen the national unified coding standards in high-value medical supplies registration, procurement, circulation, use, payment and supervision and other links of the interface application.
-
Yahong Pharma completed a D-round financing of more than RMB700 million
Time of Update: 2021-03-07
Last month, a Phase III clinical trial application for APL-1202 single-drug first-line treatment of critical non-muscle immersive bladder cancer was approved in China.
-
Drug Ming Juno, a leader in cell immunotherapy, is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-03-07
The company has established an integrated platform dedicated to the development, manufacture and commercialization of breakthrough cell immunotherapy for blood and solid tumors.
The main product, Relma-cel, is an anti-CD19 CAR-T therapy for recurring or incurable ("r/r") B-cell lymphoma, and is expected to become the first CAR-T therapy approved in China for a class of biological products.
-
The results of the winning bid of the three provincial alliances, which reduced the price by 90.35%, were announced
Time of Update: 2021-03-07
basically no small business winning bid 1, a maximum price reduction of 90.35 percent, a number of well-known arms enterprises won the bid September 5, Chongqing Municipal Health Insurance Bureau
-
It is proposed that 200 hospital representatives who intend to optimize the product line may lose their jobs
Time of Update: 2021-03-07
today, it was announced that the company will make product line adjustments in the near future, mainly related to the following four points: 200 hospital representatives, OTC representatives incr
-
The third batch of drugs centralized procurement pharmaceutical enterprises may have new changes
Time of Update: 2021-03-07
The market department has been weakened before, there are a variety of reasons, objectively is heavy digital light description, the key lies in the effectiveness, depending on the policy and enterprise's degree of importance; After the third batch of national mining, the marketing department has a new space to play, how to seize the opportunity to understand the market, and sales department to work together, will be the focus of many pharmaceutical marketing department to focus on.
-
AI new pharmaceutical company Fermizi Technology completed a cumulative hundreds of millions of yuan A round of financing
Time of Update: 2021-03-07
guo Luwei, managing partner of Tongyu Capital, said: "Tongyu Capital has long been bullish on artificial intelligence and medical health track, and the successful experience of the investment team in the past has made Tongyu Capital have a deep understanding of China's entrepreneurial environment and large health industry, corporate management, and we prefer 'super CEO'.
-
The original drug price pharmacy is 454% higher than the hospital drug price monitoring network spread
Time of Update: 2021-03-07
At the end of July, Weihai City Health Insurance Bureau issued a "notice on further doing a good job in monitoring pharmaceutical prices", proposed to use (business volume) large, strong public response, high social concern, medical insurance funds affected by the price of drugs, medical supplies and medical services in a timely manner into the scope of price monitoring, expanding the monitoring object and scope, and implement dynamic adjustment.
-
Legendary Creatures has teamed up with Noile-Immun
Time of Update: 2021-03-06
Founded in April 2015 in Tokyo, Japan, Noile-Immune is a clinical-stage biotechnology company focused on the development and commercialization of solid tumor CAR-T therapies, and its PRIME technology promotes the amplification, accumulation and induction of CAR-T and/or TCR-T cells and the patient's own T-cells in solid tumors.
-
Drug belt procurement will be normalized national price linkage sharing
Time of Update: 2021-03-06
The document points out that in order to give full play to the scale and technical advantages of the alliance, promote cross-regional joint belt volume procurement, further reduce the price of high-value medical supplies, it is proposed to start the inter-provincial recruitment alliance high-value medical supplies centralized belt procurement.
-
The promotion of clinicians under DRG: from focusing on prescription rights to focusing on diagnostic rights
Time of Update: 2021-03-06
Prescription Reflexes: A link between a patient's specific signs and symptoms and the doctor's comprehensive consideration, including the choice of a drug for a disease at the beginning of treatment and later in the course of treatment, which begins as early as the doctor is in medical school, until some external influence changes these habits, which is the prescription condition reflex effect.
-
The Fund for Innovative Biopharmaceuticals of ZHONGKIN Capital completed the fund raising
Time of Update: 2021-03-06
The related work has been highly recognized and supported by the China Securities Investment Fund Industry Association, so ZHONGKIN Qide became the first private equity investment fund to complete the filing through the "Green Channel for the filing of management products in the field of epidemic prevention and control".
-
Slow-disease diagnosis and treatment company Shuo Mao Technology completed tens of millions of strategic financing
Time of Update: 2021-03-06
As more and more hospitals obtain Internet hospital licenses and set out to establish internal Internet hospital systems, Shuo Mao Technology has the ability to help hospitals connect patients' in-hospital data in the field of respiratory departments (slow-blocking lung) and pediatrics (asthma), providing a convenient platform for remote follow-up and disease management for patients with chronic diseases.
